209 related articles for article (PubMed ID: 35451176)
21. The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease.
Brothers RO; Turrentine KB; Akbar M; Triplett S; Zhao H; Urner TM; Goldman-Yassen A; Jones RA; Knight-Scott J; Milla SS; Bai S; Tang A; Brown RC; Buckley EM
Blood; 2024 May; 143(21):2145-2151. PubMed ID: 38364110
[TBL] [Abstract][Full Text] [Related]
22. Hb S (
Tsitsikas DA; Kamal M; Braimoh A; Benson S; Abukar J
Hemoglobin; 2021 Nov; 45(6):355-357. PubMed ID: 33622152
[TBL] [Abstract][Full Text] [Related]
23. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
24. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.
Weaver SB; Akinwale H; Nonyel NP; Wingate LT
Expert Rev Hematol; 2024 Jun; 17(6):255-260. PubMed ID: 38753522
[TBL] [Abstract][Full Text] [Related]
26. Real-world data on voxelotor to treat patients with sickle cell disease.
Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
[TBL] [Abstract][Full Text] [Related]
27. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
28. Voxelotor: First Approval.
Blair HA
Drugs; 2020 Feb; 80(2):209-215. PubMed ID: 32020554
[TBL] [Abstract][Full Text] [Related]
29. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action.
Suhail M
Sci Rep; 2024 Jan; 14(1):1861. PubMed ID: 38253605
[TBL] [Abstract][Full Text] [Related]
30. Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study.
Brown C; Idowu M; Drachtman R; Beaubrun A; Agodoa I; Nguyen A; Lipman K; Moshkovich O; Murphy R; Bellenger MA; Smith W
Biomed Res Int; 2023; 2023():7533111. PubMed ID: 36748060
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
Tanriverdi LH; Sarici A; Erkurt MA; Parlakpinar H
Int J Clin Pract; 2021 Jun; 75(6):e13967. PubMed ID: 33369007
[TBL] [Abstract][Full Text] [Related]
32. Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease.
Lehrer-Graiwer J; Yokoshima L; Tong B; Love TW
Contemp Clin Trials; 2020 Nov; 98():106161. PubMed ID: 33010428
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Model-Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination.
Moody AT; Narula J; Maurer TS
Clin Pharmacol Ther; 2024 May; 115(5):1114-1121. PubMed ID: 38229405
[TBL] [Abstract][Full Text] [Related]
34. Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease.
Yenamandra A; Marjoncu D
J Adv Pract Oncol; 2020; 11(8):873-877. PubMed ID: 33489427
[TBL] [Abstract][Full Text] [Related]
35. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
36. Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE-KIDS 1 trial.
Chonat S; Fields E; Baratz H; Watt A; Pochron M; Dixon S; Tonda M; Brown C; Archer D
EJHaem; 2024 Feb; 5(1):125-130. PubMed ID: 38406531
[TBL] [Abstract][Full Text] [Related]
37. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
38. Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor.
Glaros AK; Razvi R; Shah N; Zaidi AU
Ther Adv Hematol; 2021; 12():20406207211001136. PubMed ID: 33796238
[TBL] [Abstract][Full Text] [Related]
39. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
[TBL] [Abstract][Full Text] [Related]
40. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease.
Giacomini L; Puricelli C; Sacchetti S; Zanotti V; Rolla R
Int J Lab Hematol; 2023 Dec; 45(6):831-832. PubMed ID: 37604778
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
